Facile synthetic procedures and broad spectrum of biological activities are special attributes
of sulfonamides. Sulfonamide derivatives have demonstrated potential as a class of compounds
for the treatment of Alzheimer's disease (AD). Recent sulfonamide derivatives have been reported as
prospective anti-AD agents, with a focus on analogues that significantly inhibit the function of acetylcholinesterase
(AChE) and butyrylcholinesterase (BChE) enzymes and exhibit remarkable antioxidant
and anti-inflammatory properties, all of which are critical for the treatment of AD. Sulfonamide-
mediated activation of nuclear factor erythroid 2-related factor 2 (NRF2), a key regulator of the
endogenous antioxidant response, has also been suggested as a potential therapeutic approach in AD.
Additionally, it has been discovered that a number of sulfonamide derivatives show selectivity for
the β- and γ-secretase enzymes and a significant reduction of amyloid B (Aβ) aggregation, which
have been implicated in AD. The comparative molecular docking of benzenesulfonamide and
donepezil, an AD reference drug showed comparable anti-AD activities. These suggest that sulfonamide
derivatives may represent a new class of drugs for the treatment of AD. Thus, the current review
will focus on recent studies on the chemical synthesis and evaluation of the anti-AD properties,
molecular docking, pharmacological profile, and structure-activity relationship (SAR) of sulfonamide
derivatives, as well as their potential anti-AD mechanisms of action. This paper offers a thorough
assessment of the state of the art in this field of study and emphasizes the potential of sulfonamide
derivatives synthesized during the 2012–2023 period as a new class of compounds for the
treatment of AD.